Iron Deficiency Anemia
Anemia is common among people living in low- and middle-income countries, and alleviation of the global burden of anemia is an essential global health target over the next decade. Estimates…
Introduction: The Complexity and Challenge of Preventing, Treating, and Managing Blood Diseases in the Developing Countries
Managing hematologic disorders in developing countries poses problems not encountered in Western societies. The clinical features of hematologic conditions may be modified by malnutrition, chronic bacterial infection, or parasitic illness….
Global Hematology
David J. Roberts, DPhil, MRCP, FRCPath, Editor David J. Weatherall, MD, FRCP, FRS, Editor Many common diseases exhibit marked and complex heterogeneity due to genetic and environmental factors together with…
Transfusion Considerations in Pediatric Hematology and Oncology Patients
Pediatric patients with malignancies or benign hematologic diseases are a heterogeneous group with complicated underlying pathophysiologies leading to their requirements for transfusion therapy. Common practice among pediatric hematologists, oncologists, and…
Management of Thrombotic Microangiopathic Hemolytic Anemias with Therapeutic Plasma Exchange
Thrombotic microangiopathies are a heterogeneous group of inherited and acquired disorders sharing a common clinical presentation of microangiopathic hemolytic anemia, thrombocytopenia, and organ damage. These disorders have been treated with…
Modifications to Blood Components
Blood component modifications can be performed by the hospital blood bank for select clinical indications. In general, modification of blood components increases costs and may delay availability of the blood…
Management of the Platelet Refractory Patient
Platelet refractoriness occurs when there is an inadequate response to platelet transfusions, which typically has nonimmune causes, but is also associated with alloantibodies to human leukocyte antigens (HLAs) and/or human…
Red Blood Cell Antibodies in Hematology/Oncology Patients
Red blood cell (RBC) transfusion is a cornerstone of the management of patients with hematology/oncology disorders. However, a potentially deleterious consequence of transfusion is the development of alloantibodies against blood…
Pathogen Inactivation Technologies
Pathogen inactivation technologies represent a shift in blood safety from a reactive approach to a proactive protective strategy. Commercially available technologies demonstrate effective killing of most viruses, bacteria, and parasites…
Transfusion Reactions
Transfusion reactions are common occurrences, and clinicians who order or transfuse blood components need to be able to recognize adverse sequelae of transfusion. The differential diagnosis of any untoward clinical…
